MedTrace Logo

Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products

NCT00455585 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2008-02-08

No results posted yet for this study

Summary

This study aims to compare the steady state pharmacokinetics of stavudine, lamivudine, and nevirapine in HIV positive Ugandan patients taking Triomune 40 with the pharmacokinetics of the originator products known as Viramune, Epivir and Zerit 40.

Conditions

  • HIV Infections

Interventions

DRUG

nevirapine, stavudine, lamivudine

Sponsors & Collaborators

  • Department of Foreign Affairs, Ireland

    collaborator OTHER_GOV

  • Makerere University

    lead OTHER

Principal Investigators

  • Concepta Merry, PhD · University of Dublin, Trinity College

  • Keith McAdam · Infectious Diseases Institute, Makerere University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2007-05-31
Completion
2007-11-30

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00455585 on ClinicalTrials.gov